
|Articles|October 1, 2002
Developing neuroprotective drugs for glaucoma no easy task
Neuroprotection is a concept that originated in the CNS community with the development of therapies aimed at preventing or retarding the manifestations of disorders such as Parkinson's and Alzheimer's diseases, stroke, and head trauma. Less than 15 years ago, the ophthalmic community began to discuss this concept as a novel way to preserve vision in disorders of the retina.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5













































.png)


